Fundraising FoxKynexis
4 known investors
Find your way into Kynexis
Sign up to find every way you can get introduced to Kynexis
- Your email: who you already know at Kynexis, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Kynexis team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Kynexis is a clinical-stage biotech developing KYN-5356, an oral small-molecule KAT-II inhibitor targeting the kynurenine pathway to improve cognition in neurological diseases. Its lead program is in a Phase 2 trial for cognitive impairment associated with schizophrenia (CIAS), with expansion planned into Alzheimer's disease.
Founders & leadership
Investors · 4
How we know: Ysios Capital's portfolio page · the company's own site · the VCSheet dataset · Not right? Tell us
How we know: the company's own site · a partner's Signal profile · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
In the news
Frequently asked questions
- What does Kynexis do?
- Kynexis is a clinical-stage biotech developing KYN-5356, an oral small-molecule KAT-II inhibitor targeting the kynurenine pathway to improve cognition in neurological diseases. Its lead program is in a Phase 2 trial for cognitive impairment associated with schizophrenia (CIAS), with expansion planned into Alzheimer's disease.
- Who founded Kynexis?
- Kynexis was founded by Robert Schwarcz, Carol Tamminga, Christer Köhler.
- Who are Kynexis's investors?
- Kynexis's investors include Ysios Capital, Forbion, Novartis Venture Fund, Sunstone Capital.